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Abstract
Little data are available on access strategy outcomes for cardiac catheterizations in patients with prior coronary artery bypass
graft surgery (CABG). We investigated the effect of transradial access (TRA) and transfemoral access (TFA) on short-term major
vascular complications (MVC) and long-term major adverse cardiovascular events (MACE). In this single-center, retrospective
cohort study, 1084 patients met our inclusion criteria (TRA ¼ 469; TFA ¼ 615). The cumulative incidence for the primary safety
endpoint MVC at 30 days (a composite of major bleeding, retroperitoneal hematoma, dissection, pseudoaneurysm, and arter-
iovenous fistula) was lower with TRA (0.7% vs 3.0%, P < .01) and this difference remained significant after propensity score
adjustment (odds ratio: 0.24; 95% CI, 0.07-0.83; P ¼ .024). The cumulative incidence for the primary efficacy endpoint MACE at
36 months (a composite of all-cause mortality, myocardial infarction, stroke, and urgent target vessel revascularization) was 28.6%
with TRA and 27.6% with TFA, respectively. Kaplan-Meier curves showed no difference for the primary efficacy endpoint
(P¼ .65). Contrast use (mL) was significantly lower with TRA (130 [100-180] vs 150 [100-213], P < .01). In conclusion, in patients
with prior CABG, TRA was associated with significantly fewer short-term MVC and contrast use, but not with a difference in
long-term MACE, compared with TFA.
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Introduction
Transradial access (TRA) is the first choice for coronary angio-
graphy (CA) and percutaneous coronary intervention (PCI) in
current clinical practice.1-3 Several randomized controlled
trials (RCTs) and meta-analyses have shown that TRA is super-
ior to transfemoral access (TFA) in terms of vascular compli-
cations and major bleeding.4-7 Furthermore, most of these
studies did not observe differences in short-term and 1-year
major adverse cardiovascular events (MACE).4-6,8
Whether this also holds true for patients with prior coronary
artery bypass graft surgery (CABG) is unclear. Studies compar-
ing access site strategy in these patients are limited, despite the
fact that CA and PCI are regularly performed in this population.
Consequently, patients with prior CABG still have a high like-
lihood of TFA over TRA.9-11 In the RIVAL (radial versus
femoral access for CA and intervention in patients with acute
coronary syndromes) and MATRIX (radial versus femoral
access and bivalirudin versus unfractionated heparin in inva-
sively managed patients with acute coronary syndrome) study,
prior CABG was not an exclusion criterion.4,5 Nevertheless, few
patients with a history of CABG were included and data were not
analyzed separately. Some observational studies did compare
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TRA with TFA in these patients. They showed lower rates of
vascular and bleeding complications in the TRA group, but no
differences in MACE rate up to 1-year.10-14 The only RCT so far
did not find differences in MACE or vascular complications.15
To our knowledge, studies comparing the impact of access
strategy on long-term clinical outcomes are not available for
patients with prior CABG. Furthermore, data on vascular com-
plications for this subset of patients undergoing CA and PCI are
still limited.
The aim of this study was to investigate the effect of TRA
and TFA on short-term major vascular complications (MVC)
and long-term MACE.
Materials and Methods
Study Design and Patient Population
We conducted a single-center, retrospective cohort study to
compare TRA and TFA for cardiac catheterization in CABG
patients. From July 2010 to December 2017, 1106 consecutive
patients with a history of CABG underwent CA or PCI in our
tertiary care institution. Patients with a brachial or ulnar arterial
access, a radial artery used as bypass graft and a heart trans-
plant after CABG were excluded. If multiple procedures were
performed during the study period, patients were included at
their first CA or PCI. The Ethics Committee of the Erasmus
Medical Center approved the research proposal and concluded
that the study was not subject to the Dutch Research on
Humans Subjects Act, renouncing the need for patient
informed consent.
Procedure Description
Multiple interventional cardiologists performed the CA and
PCI procedures during the study period. The selection for TRA
or TFA was made at the operator’s discretion. Arterial access
was obtained via the right or left radial artery in the TRA group
and via the right or left common femoral artery in the TFA
group. If arterial crossover was performed, the initial access
site was decisive for placement in the TRA or TFA group.
Procedural success for PCI was defined as successful stent
placement, unless it was stated that the lesion was only treated
with balloon inflation. Hemostasis was acquired by a transra-
dial compression device in the TRA group and by an arterial
closure device or by manual compression in the TFA group. All
procedures were performed according to the standard of prac-
tice at that time and periprocedural medication was given in
line with treatment protocols, including heparin and in case of
TRA a cocktail of verapamil and nitroglycerin. Patients under-
going PCI were loaded with aspirin and a P2Y12 inhibitor
(clopidogrel, prasugrel, or ticagrelor).
Study Endpoints
To assess for outcome differences between TRA and TFA,
we determined a primary safety endpoint and a primary efficacy
endpoint. The primary safety endpoint was defined as MVC, a
composite of non-CABG-related major bleeding, retroperitoneal
hematoma, dissection, pseudoaneurysm, and arteriovenous fis-
tula at 30 days after the procedure. A non-CABG-related major
bleeding was specified as a “Bleeding Academic Research Con-
sortium” (BARC) type 3 or 5 bleeding.16 The primary efficacy
endpoint was defined as long-term MACE, a composite of
all-cause mortality, myocardial infarction (MI), stroke, and
urgent target vessel revascularization (UTVR). We performed
censoring at 36 months, as at least 50% of follow-up was available
for the total study population. Stroke and MI were diagnosed by
the treating physician according to standard guidelines at the time
of event, and UTVR was described as a repeat PCI of the same
coronary artery in patients with unstable angina,
non-ST-elevation MI, and ST-elevation MI. The individual com-
ponents of the primary safety and efficacy endpoint were defined
as secondary safety and efficacy endpoints. Furthermore, major
bleeding subtypes (BARC type 3 A/B/C, transfusion, type 5 A/B),
minor and overall bleeding at 30 days were examined. Minor
bleeding was defined as a BARC type 1 or 2 bleeding (16). Over-
all bleeding included both non-CABG-related major bleeding and
minor bleeding.
Data Collection
We extracted baseline and procedural data from the hospital’s
electronic medical record system, as well as data on MVC and
bleeding. The occurrence of MACE since the procedure was
assessed for each patient individually between May and July
2019. Data on mortality were obtained from the municipal civil
registry. If follow-up data were not available in the medical
records, we collected information on patient follow-up using a
written questionnaire or telephone survey. Only if necessary
and after patient’s permission, the treating physician was con-
tacted to complete data collection.
Statistical Analysis
Continuous variables were presented as medians (25th-75th
percentiles) and compared using the Mann-Whitney U test.
Categorical variables were expressed as percentages (%) and
compared with Pearson w2 test or Fisher exact test, as appro-
priate. To investigate differences in efficacy endpoints between
TRA and TFA, Kaplan-Meier curves were drawn and log-rank
tests were performed. Patients were followed-up until the time
of the event or until the date of last contact, at which time point
they were censored. To investigate differences in all safety
outcomes and bleeding between both access sites, Pearson w2
test or Fisher exact test was used. Subsequently, logistic regres-
sion models with complete case analysis (n ¼ 1043) were used
to determine whether TRA was associated with MVC and
bleeding. First, we performed univariable analysis. Results
were expressed as odds ratios (ORs) with 95% CIs. To perform
multivariable analysis, we used propensity score (PS) adjust-
ment because of the limited number of available events
per variable. The PS was calculated for each patient using
logistic regression with access site (TRA or TFA) as the depen-
dent variable. We selected the following clinically relevant
independent variables in the PS model: age, sex, hypertension,
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hypercholesterolemia, diabetes, family history, current smok-
ing, prior stroke, prior MI, prior PCI, peripheral artery disease,
chronic kidney disease, CABG anatomy known, CA or PCI
within 48 hours post-CABG, type of graft(s) used,
ST-elevation MI, PCI performed, sheath size (6F), type of ves-
sel treated, lesion class B2 or C, implanted stents, total stent
length, procedure time, fluoroscopy time, radiation exposure
(dose area product), use of glycoprotein inhibitor, and use of
thienopyridine derivate. We then performed multivariable
logistic regression with the calculated PS and TRA as indepen-
dent variables. Adjusted ORs with 95% CIs were thus obtained.
SPSS version 25.0 was used for statistical analyses. A 2-sided
P < .05 was considered significant.
Results
Baseline Characteristics
A total of 1084 patients with a history of CABG who underwent
CA or PCI were included in the study. Of the 1106 consecutive
patients who were evaluated, 22 were excluded due to brachial
arterial access (n¼ 4), ulnar arterial access (n¼ 4), heart trans-
plant after CABG (n ¼ 8), and a radial artery used as a bypass
graft (n¼ 6). The baseline characteristics are shown in Table 1.
Arterial access was obtained through TRA in 469 patients and
through TFA in 615 patients. Patients in the TRA group were
significantly older than those in the TFA group. Prevalence of
cardiovascular risk factors was high in both groups, but did not
differ significantly, except for a family history of cardiovascular
disease. Patients in the TFA group had more often ST-elevation
MI at clinical presentation or CABG in the previous 48 hours.
Furthermore, graft anatomy was known before cardiac catheter-
ization in the great majority of patients and did not differ signif-
icantly between TRA and TFA.
Procedural Characteristics
The procedural characteristics are shown in Table 2. Percuta-
neous coronary intervention was performed in 699 (64.5%)
patients and CA was performed in the remaining 385 (35.5%)
cases. Percentage of PCI and success rates for PCI were com-
parable for both the TRA and TFA group. Native coronary
arteries were more often treated through TRA, while grafts were
more often treated through TFA. Access site crossover occurred
significantly more often from TRA to TFA, than vice versa. Use
of a 5F sheath was more common with TRA, while use of a 6F
sheath was more common with TFA. Use of a 7F sheath did not
differ significantly between both access sites. The use of only
aspirin after the procedure was less in the TRA group, while use
of triple anticoagulation therapy was more in the TRA group.
Table 1. Baseline Characteristics.a
Variable Total (n ¼ 1084) TRA (n ¼ 469) TFA (n ¼ 615) P
Age (years) 72 [65-77] 72 [66-78] 71 [65-77] .018
Male 853/1084 (78.7) 370/469 (78.9) 483/615 (78.5) .89
Hypertension 876/1082 (81.0) 388/468 (82.9) 488/614 (79.5) .16
Hypercholesterolemia 868/1082 (80.2) 383/468 (81.8) 485/614 (79.0) .24
Diabetes 388/1082 (35.9) 163/468 (34.8) 225/614 (36.6) .54
Family History 349/1082 (32.3) 135/468 (28.8) 214/614 (34.9) .036
Current Smoker 104/1082 (9.6) 39/468 (8.3) 65/614 (10.6) .21
Prior Stroke 172/1082 (15.9) 75/468 (16.0) 97/614 (15.8) .92
Prior MI 516/1082 (47.7) 211/468 (45.1) 305/614 (49.7) .13
Prior PCI 440/1082 (40.7) 183/468 (39.1) 257/614 (41.9) .36
Peripheral artery disease 267/1082 (24.7) 110/468 (23.5) 157/614 (25.6) .44
Chronic kidney disease 283/1083 (26.1) 120/469 (25.6) 163/614 (26.5) .72
Clinical presentation
Stable angina 405/1084 (37.4) 179/469 (38.2) 226/615 (36.7) .63
Unstable angina/NSTEMI 392/1084 (36.2) 178/469 (38.0) 214/615 (34.8) .28
STEMI 130/1084 (12.0) 34/469 (7.2) 96/615 (15.6) <.01
Other 157/1084 (14.5) 78/469 (16.6) 79/615 (12.8) .08
CABG
Time since (years) 12 [4-18] 12 [5-19] 12 [4-18] .16
Graft anatomy known 1051/1084 (97.0) 457/469 (97.4) 594/615 (96.6) .42
In patients with STEMI 118/130 (90.8) 31/34 (91.2) 87/96 (90.6) .92
CA/PCI < 48 hours 73/1084 (6.7) 13/469 (2.8) 60/615 (9.8) <.01
LIMA used 920/1084 (84.9) 399/469 (85.1) 521/615 (84.7) .87
RIMA used 116/1084 (10.7) 61/469 (13.0) 55/615 (8.9) .032
SVG used 974/1084 (89.9) 417/469 (88.9) 557/615 (90.6) .37
Abbreviations: CA, coronary angiography; CABG, coronary artery bypass graft; LIMA, left internal mammary artery; MI, myocardial infarction; NSTEMI, non-ST-
elevation myocardial infarction; PCI, percutaneous coronary intervention; RIMA, right internal mammary artery; STEMI, ST-elevation myocardial infarction;
SVG, saphenous vein graft; TFA, transfemoral access; TRA, transradial access.
Bold values highlight the statistical significance.
aValues are median (interquartile range) or n (%).
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Procedure and fluoroscopy time (minutes) were comparable for
both groups, but radiation exposure (cGycm2) and contrast use
(mL) were significantly lower in the TRA group.
Trends in TRA Use and Data Collection
In 2015, TRA became the preferred choice for CA and PCI in
patients with a history of CABG at our center (Figure 1). Dur-
ing the study period, proportion TRA increased significantly
over the years compared with TFA (P for trend <.01). TRA
expanded from 9% in 2010 to 69.2% in 2017. In 2016, 77.9% of
the procedures were performed through TRA. As shown in
Tables 1 to 3, baseline and procedural characteristics were
largely complete (>95%) and loss to follow-up percentages
were low at 30 days (<3%).
Safety Endpoints and Bleeding
As shown in Table 3, MVC occurred significantly less often in
the TRA group, as did major bleeding. Aneurysm did not differ
significantly between the two groups. For the other secondary
safety outcomes, no statistical tests were performed because of
the low numbers of events. Occurrence of minor and overall
bleeding was significantly lower in the TRA group.
In the univariable analysis, TRA was associated with fewer
MVC, major bleeding, minor bleeding, and overall bleeding
(Table 4). After PS adjustment in the multivariable analysis,
TRA turned out to be independently associated with lower rates
of MVC, major bleeding, minor bleeding, and overall bleeding
(Table 4). The PS model, with all variables included, is shown
as supplemental material (supplement 1).
Efficacy Endpoints
At 36 months, the cumulative incidence of MACE was 28.6%
(134 events) for the TRA group and 27.6% (170 events) for the
TFA group, respectively. Kaplan-Meier curves for the TRA
and TFA group showed no difference for the primary efficacy
endpoint (P ¼ .65; Figure 2). In addition, for the secondary
Table 2. Procedural Characteristics.a
Variable Total (n ¼ 1084) TRA (n ¼ 469) TFA (n ¼ 615) P
Access site crossover 35 (3.2) 31 (6.6) 4 (0.7) <.01
Sheath size
5F 20 (1.8) 20 (4.3) 0 (0.0) <.01
6F 1046 (96.5) 445 (94.9) 601 (97.7) .018
7F 18 (1.7) 4 (0.8) 14 (2.3) .07
PCI performed 699 (64.5) 309 (65.9) 390 (63.4) .40
Procedural success 665 (95.1) 297 (96.1) 368 (94.4) .28
Vessel treated
Native 361 (51.6) 178 (57.6) 183 (46.9) <.01
Graft 202 (28.9) 76 (24.6) 126 (32.3) .025
Multiple 136 (19.5) 55 (17.8) 81 (20.8) .33
Lesion classb
Class A 9 (1.3) 6 (1.9) 3 (0.8) .19
Class B1 63 (9.0) 32 (10.4) 31 (7.9) .27
Class B2 145 (20.7) 67 (21.7) 78 (20.0) .59
Class C 482 (69.0) 204 (66.0) 278 (71.3) .14
Implanted Stents 1 [1-2] 1 [1-2] 1 [1-2] .20
Stent length (mm) 27 [16-46] 27 [16-45] 27 [16-48] .61
Stent used 651 (93.1) 290 (93.9) 361 (92.6) .50
Drug-eluting stent 638 (98.0) 285 (98.3) 353 (97.8) .42
Bare Metal Stent 7 (1.1) 3 (1.0) 4 (1.1) 1.00
Other 6 (0.9) 2 (0.7) 4 (1.1) .70
Embolic protection device 49 (4.5) 21 (4.5) 28 (4.6) .95
Procedure time (minutes) 61 [43-83] 61 [45-83] 61 [42-83] .67
Fluoroscopy time (minutes) 15 [9-24] 15 [10-23] 15 [9-24] .51
Radiation exposure (cGycm2) 5186 [3168-8805] 4608 [2974-7274] 5828 [3473-9711] <.01
Contrast (mL) 150 [100-200] 130 [100-180] 150 [100-213] <.01
Glycoprotein inhibitor 55 (5.1) 17 (3.6) 38 (6.2) .60
Medication at discharge
Aspirin only 190 (17.5) 68 (14.5) 122 (19.8) .022
Dual antiplatelet therapy 759 (70.0) 332 (70.8) 427 (69.4) .63
Triple anticoagulation therapy 122 (11.3) 67 (14.3) 55 (8.9) <.01
Abbreviations: PCI, percutaneous coronary intervention; TFA, transfemoral access; TRA, transradial access.
Bold values highlight the statistical significance.
aValues are median (interquartile range) or n (%).
bLesion class of the most severe lesion, if multiple were treated.
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efficacy endpoints (all-cause mortality, MI, stroke, and
UTVR), no significant differences were observed.
Discussion
This study compared TRA with TFA for CA and PCI in
patients with prior CABG, in terms of short-term safety and
long-term efficacy outcomes. The main findings are (1) TRA
was associated with significantly fewer MVC at 30 days, (2) no
difference was observed in MACE at 36 months between TRA
and TFA, and (3) contrast use was significantly less with TRA.
Our study showed that TRA was associated with less
MVC, which remained significant after PS adjustment. The
significant difference in favor of TRA was mainly driven by a
lower rate of major bleeding, despite a higher percentage of
triple anticoagulation therapy. Our findings are opposite to
the findings of the RCT by Michael et al,15 in which they
compared TRA and TFA in 128 patients with prior CABG.
The primary endpoint of the study was the volume of contrast
use during the procedure but also vascular complications were
recorded. They reported no difference in vascular complica-
tions and in-hospital major bleeding between both access
sites, using the same BARC definitions. Possible explanations
for this difference are the follow-up time, as follow-up
stopped at hospital discharge in their study, and the small
sample size, as it was not powered to find a difference in
vascular complications or bleeding. A recently published
RCT compared net procedure time (time from sheath intro-
duction to procedure completion) for left-TRA with TFA in
150 patients with prior CABG and reported no difference for
the secondary outcome of local vascular complications.17
However, as this was only a secondary endpoint, this study
was probably not powered for this endpoint. Another recent,
large retrospective trial that included 58 870 patients found
similar results with our study.10 They showed that TRA was
associated with fewer arterial complications and in-hospital
major bleeding. However, they analyzed these in-hospital out-
comes separately, while we used a composite outcome that
included both vascular complications and major bleeding at
30 days. The only meta-analysis on this subject included 9
studies up to October 2015.18 TRA was associated with fewer
access site complications, but definitions were different for
each study. Summarizing these studies and with the current
clinical practice in mind, TRA seems to be at least as safe as
TFA in patients with prior CABG.
To our knowledge, this is the first study presenting
long-term clinical outcomes for TRA and TFA in patients
with prior CABG. The Kaplan-Meier curves did not differ
significantly for long-term MACE and each single component
of MACE. In the aforementioned study by Michael et al,
in-hospital MACE was a secondary outcome, defined as
all-cause mortality, MI, stroke, and UTVR.15 During the
study period, none of these events occurred. This might be
due to small sample size, short follow-up time, and the exclu-
sion of old patients (age >90 years) and ST-elevation MI.
Furthermore, there are some retrospective studies comparing
clinical outcomes for both access sites. Two small studies did
not find any difference for MACE at 1-year follow-up.12,13
The large retrospective study did not use MACE as a compo-
site endpoint.10 However, the adjusted TRA and TFA
Kaplan-Meier curves for 1-year mortality did not show any
significant difference. In our study, 1-year clinical outcomes
were not a study endpoint, but TRA and TFA Kaplan-Meier
curves for this time period are provided as supplemental mate-
rial (supplement 2). No significant differences for 1-year
MACE, and each individual component of MACE, were
observed among these access sites. Altogether, it seems that
the choice for TRA or TFA in patients with prior CABG does
not affect MACE.
In the present study, we show the transformation of TRA as
preferred access site in this subset of patients, just as Kinnaird
et al did in the United Kingdom.10 However, when compared
with the overall population, in over 85.0% of PCI procedures
performed in the Netherlands between 2017 and 2018, TRA
was used.19 A possible explanation for the fact that TRA still
lags behind in patients with prior CABG might be the ignor-
ance of CABG anatomy in the acute setting through missing
data (surgery reports). However, in our study CABG anatomy
was known in the great majority of patients presenting with
STEMI and access site did not differ significantly in these
patients if CABG anatomy was unknown. In addition, ima-
ging the left internal mammary artery is more effective
through TFA and left TRA than through right TRA,20 but left
TRA has its ergonomic disadvantages.21 Furthermore, poten-
tial disadvantages of TRA, such as higher crossover rates
might explain the preference for TFA. In our study, arterial
crossover occurred significantly more from TRA to TFA, than
vice versa. The main reasons for crossover were not obtaining
arterial access, inability to advance the catheter, and radial
spasm. These issues were also described in the literature.22-24
Figure 1. Access site for coronary angiography and percutaneous
coronary intervention in patients with prior coronary artery bypass
graft surgery; use of TFA and TRA over time (2010-2017). TFA
indicates transfemoral access; TRA, transradial access.
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Other studies also reported more arterial crossover with
TRA,12,13,15,17,18 except for one study which found a slightly
higher crossover rate from TFA to TRA.11 In our study, the
higher arterial crossover rate from TRA to TFA did not lead to
longer procedure duration in the TRA group, as procedure time
was comparable for both access sites. Other more recent studies
also observed no significant differences in procedure time
between TRA and TFA.11,12,17,18
We found that radiation exposure (dose area product) was
significantly lower with TRA compared with TFA. However,
this might be more a reflection of refinement of radiation use
over time during cardiac catheterization. For example, the use
of fluoroscopy became the standard supportive tool for stent
placement and balloon inflation instead of filming (cine).
This is supported by the fact that there was no difference
in fluoroscopy time. A recent prospective trial also showed
no significant differences in radiation exposure and fluoro-
scopy time.17
Finally, contrast use in cardiac catheterizations remains an
important topic and one should always minimize this, as its
usage can lead to contrast-induced acute kidney injury. This
serious complication has kidney-related consequences and may
even affect long-term outcomes.25 The lower contrast volume
use with TRA in the present study differs from the findings of
Michael et al.15 They reported higher contrast use in the TRA
group for CA and no difference in contrast use for PCI between
both access sites. Furthermore, Rigattieri et al observed no
difference between TRA and TFA.18 This discrepancy might
be explained by the fact that our study covered a later time
period in which TRA use and techniques had improved. The
recent studies by Hirzallah et al and Dai et al support this
assumption.11,12 Tsigkas et al found a nonsignificant difference
in contrast use between both access sites.17
Study Limitations
This study has some limitations. Firstly, it was a retrospective
study. Selection bias and other forms of bias resulting from lack
of randomization might have influenced results. To account for
this, a PS model was used to correct for potential differences in
characteristics of patients assigned to TRA or TFA.26 Sec-
ondly, underreporting of outcomes might have occurred due
to suboptimal documentation by treating physicians and
patients. Thirdly, the activated clotting time (ACT) was mea-
sured according to local protocol, but not systematically regis-
tered during most of the study period. Consequently, we were
not able to present these data and could not adjust for a possible
longer ACT in the TRA or TFA access group. Fourthly, the
high rate of early CA and PCI after CABG is a noteworthy
limitation, as establishing bleeding cause in these patients can
Table 3. Major Vascular Complications and Bleeding at 30 Days.a
Outcome Total (n ¼ 1084) TRA (n ¼ 469) TFA (n ¼ 615) P
Major vascular complications 21/1061 (2.0) 3/458 (0.7) 18/603 (3.0) <.01
Major bleedingb 18/1061 (1.7) 2/458 (0.4) 16/603 (2.7) <.01
Type 3a 10/1061 (0.9) 2/458 (0.4) 8/603 (1.3) .14
Transfusion 4/1061 (0.4) 1/458 (0.2) 3/603 (0.5) .64
Type 3b 5/1061 (0.5 0/458 (0.0) 5/603 (0.8) .07
Type 3c 1/1061 (0.1) 0/458 (0.0) 1/603 (0.2) c
Type 5a 1/1061 (0.1) 0/458 (0.0) 1/603 (0.2) c
Type 5b 1/1061 (0.1) 0/458 (0.0) 1/603 (0.2) c
Aneurysm 3/1061 (0.3) 0/458 (0.0) 3/603 (0.5) .26
Dissection 2/1061 (0.2) 1/458 (0.2) 1/603 (0.2) c
Retroperitoneal bleeding 1/1061 (0.1) 0/458 (0.0) 1/603 (0.2) c
Arteriovenous fistula 0/1061 (0.0) 0/458 (0.0) 0/603 (0.0) c
Minor bleeding 77/1061 (7.3) 23/458 (5.0) 54/603 (9.0) .014
Overall bleedingd 94/1061 (8.9) 25/458 (5.5) 69/603 (11.4) <.01
Abbreviations: TFA, transfemoral access; TRA, transradial access.
Bold values highlight the statistical significance.
aValues are n (%).
bAccording to BARC classification.
cNo statistical test was performed because of low number of events.
dIncludes major and/or minor bleeding.
Table 4. Uni- and Multivariable Analysis for Transradial Access as
Predictor for Major Vascular Complications and Bleeding.a
Outcome Univariable P Multivariableb P
Major vascular
complications
0.21 (0.06-0.73) .014 0.24 (0.07-0.83) .024
Major bleeding 0.16 (0.04-0.70) .015 0.21 (0.05-0.93) .040
Minor bleeding 0.54 (0.33-0.89) .016 0.49 (0.29-0.83) <.01
Overall bleedingc 0.45 (0.28-0.72) <.01 0.44 (0.27-0.72) <.01
aValues are odds ratios (ORs) with 95% CIs.
bAdjusted for propensity score.
cIncludes major and/or minor bleeding.
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be challenging. Finally, ultrasound guidance was not com-
monly used to obtain TFA during the study period. Nowadays,
the use of this cotemporary technique is far more common and
reduces vascular complications.27 Therefore, this is an impor-
tant detail to take into account when interpreting these study
results.
Conclusion
In this retrospective study, the use of TRA for cardiac cathe-
terizations in patients with prior CABG was associated with
significantly fewer short-term MVC and contrast use, but not
with a difference in long-term MACE, compared with TFA.
Figure 2. Long-term Kaplan-Meier curves for the composite primary efficacy endpoint (major adverse cardiovascular events) and each
individual component. Survival plots (36 months) for transfemoral versus transradial access. MACE indicates major adverse cardiovascular
events; TFA, transfemoral access; TRA, transradial access; UTVR, urgent target vessel revascularization.
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